ArticleTranslational andrology and urology2025
Fisetin-mediated PPAR-γ upregulation: a novel therapeutic approach for corpus cavernosum smooth-muscle-cell apoptosis and restoration of erectile function after cavernous nerve injury.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of Fisetin in the Mammalian Reproductive System.Veterinary sciences · 2026Review
- Effect of lumbrokinase on a rat model of hyperlipidemia-induced erectile dysfunction.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The development of neurogenic erectile dysfunction (NED) is closely associated with apoptosis and fibrosis of corpus cavernosum smooth muscle cells (CCSMCs) following cavernous nerve injury (CNI). This study aimed to examine the preventative effects of fisetin on CCSMC apoptosis and fibrosis, as well as its ameliorative effects on NED, using a rat model of CNI. Methods: Twenty-four male Sprague-Dawley rats were randomly assigned into three groups: a control group (n=8), a model group (CNI; n=8), and a fisetin group [2.5 mg/(kg·day) of fisetin administered via gavage; n=8]. The animal model was established through clamping of the bilateral cavernous nerves. The control and model groups were given an equivalent volume of saline. Erectile function (EF) was evaluated as the ratio of intracavernous pressure to mean arterial pressure (ICP/MAP). Penile tissue samples were collected for Western blotting, Real-time polymerase chain reaction (RT-qPCR), and fluorescence analysis to assess the expression levels of apoptotic proteins, messenger RNA (mRNA), collagen types I (Col-1) and III (Col-3), and peroxisome proliferator-activated receptor gamma (PPAR-γ). Apoptosis in CCSMCs was evaluated using TUNEL staining, while the collagen content in corporal tissue was assessed using Masson staining. Results: Compared to the control group, the model group's ICP:MAP ratio decreased. The model group also exhibited increased levels of apoptotic proteins and their RNA, including caspase 3, caspase 9, and Bax, while those of Bcl-2 were decreased. TUNEL staining indicated the presence of apoptosis in CCSMCs. The expression of the Col-1 and Col-3 proteins was elevated, and Masson staining indicated that the smooth muscle-to-collagen ratio was decreased. Moreover, RT-qPCR and immunofluorescence staining indicated a decrease in PPAR-γ content in corporal tissue. Treatment with fisetin for 4 weeks reversed these changes. Conclusions: Fisetin may exert a protective effect against CNI-induced apoptosis in CCSMCs, ameliorate the fibrosis of the corporal tissue, and enhance EF, primarily through the upregulation of PPAR-γ expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.